简体|繁體
Beifu®shuhui capsules
Specification
0.35g/ capsule, 60 capsules / bottle
Introduction

Beifu®shuhui is a new generation of eye health care product researched and developed by Essex Bio-Pharmaceutical Company Limited independently, which has the effect of delaying the progress of age-related macular degeneration (AMD) and alleviating the asthenopia.

Mechanism

Beifu®shuhui is a health food made of the extract of Vaccinium myrtillusan, lutein, extracts of chrysanthemum and ginkgo leaf as the main raw materials. Vaccinium myrtillus contains anthocyanin which can strengthen the regeneration of rhodopsin (the main material for eye function) of eyes; lutein is an important part of macular pigment, which has a protective effect (antioxidation and photoprotection) on macula retinae.

Features

Concentration up to standard: lutein (10 mg/day) verified by the Age-related Eye Disease Study 2 (AREDS2) of the United States, and it is safe and effective for reducing the risk of advanced AMD;
Balanced supplement: It can supply macular pigment, rhodopsin and other various eye pigments;
Highly efficient transfer: the extract of ginkgo leaf improves fundus microcirculation and increases transfer efficiency of the effective components from the plasma to the retina;
Adequate absorption: the extract of chrysanthemum helps faster and better absorption of lutein in the body and improve absorptivity.

Application

Population with fundus ocular diseases: age-related macular degeneration, retinal pigment epithelial degeneration, vitreous turbidness, diabetic retinopathy and other retinal diseases;
Population with asthenopia: students, drivers, office workers who often use computers, and population whose work requires the eyes to focus on tiny and precise object and so on;
Population with visual impairments: pathologic myopia, high myopia, amblyopia, pseudomyopia;
Other population: senile cataract, nyctalopia, glaucoma and so on.